Electronic Reporting Option

Sign up for monthly electronic reporting today. The process is quick and simple – a hyperlink is sent to you each month and no log-in and password are required.

Sign Up Now

ADR tips of the month

The “ADR Tip of the Month” is an educational tool on adverse drug reaction topics that is sent to participants on a monthly basis to build support and awareness of the Adverse Drug Reaction study, facilitating case ascertainment, and impacting new information relating to the study or broader ADR surveillance topics.

Health Canada may use this format to complement the ADR study by providing relevant, timely drug information.

Open
2005
Ayurvedic medicinal products – Heavy metal poisoning
Open
2005
Camphor and/or eucalyptus oils
Open
2005
Ceftriaxone (Rocephin®)-induced immune hemolytic anemia (IHA)
Open
2005
Cold medications – Safety information
Open
2005
DIANE®-35 – Safety information
Open
2005
Ibuprofen and nephrotoxicity
Open
2005
Medroxyprogesterone acetate (Depo-Provera®) – Safety information
Open
2005
Valproic acid (Depakene®, Epival®)
Open
2006
ADHD medications
Open
2006
Cefprozil (Cefzil®)
Open
2006
Energy drinks – Safe use
Open
2006
Infliximab (Remicade™) and hepatosplenic T-cell lymphoma
Open
2006
Neuroleptic malignant syndrome
Open
2006
Natural health products
Open
2006
Topiramate (Topamax®) ‒ induced metabolic acidosis
Open
2008
Acetaminophen – Overdose with therapeutic use?
Open
2008
Carbamazepine-induced severe skin reactions
Open
2008
Minocycline-induced pseudo-tumor cerebri
Open
2008
Succinylcholine-induced major toxic effects
Open
2009
Codeine and breast milk transmission
Open
2009
Desmopressin (DDAVP®) – Risk of hyponatremia
Open
2009
Fentanyl-induced muscular rigidity
Open
2009
Ibuprofen – Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
Open
2009
Purple glove syndrome – Rare complication of intravenous phenytoin
Open
2009
Tamiflu™ – Possible side effects
Open
2010
Complementary and alternative medicine
Open
2010
Fluticasone (Flovent™) – Risk of adrenal suppression
Open
2010
Hormonal contraception and drug interactions
Open
2010
Metoclopramide – Risk of tardive dyskinesia
Open
2010
Montelukast (Singulair™) – Risk of psychiatric adverse reactions
Open
2010
St. John’s Wort (Hypericum perforatum) – Benefits and risks
Open
2010
Topical anesthetics-induced methemoglobinemia
Open
2011
Atomoxetine (Strattera™) – Cardiovascular risks
Open
2011
Midazolam – Allergic reactions and seizures (update)
Open
2011
Olanzapine – Risk of oculogyric crisis
Open
2011
Over-the-counter drugs for colds
Open
2011
Oxybutin – Risk of CNS complications
Open
2011
Serotonin toxicity
Open
2011
Yasmin® and Yaz®
Open
2011
The importance of ADR reporting
Open
2011
Measuring oral liquid medications in the home
Open
2011
Buying prescription drugs online – a dangerous game
Open
2011
Top 10 paediatric prescriptions in 2010
Open
2012
Adulterated health products – Health risks
Open
2012
Doxycycline-induced esophagitis
Open
2012
Fluoroquinolone-induced side effects
Open
2012
Minocycline – Risk of lupus erythematosus and autoimmune hepatitis
Open
2012
Peanut oil-containing products
Open
2012
Psychostimulants and hallucinations
Open
2012
Second-generation antipsychotics – Cardiometabolic effects